CHARMACY PHAR2289.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, CHARMACY PHAR (2289.HK) trades at a P/E of 11.00x, P/B of 0.85x, P/S of 0.11x, and a dividend yield of 6.26%.
Longitudinal percentile comparison: P/E sits at the 10th percentile over the trailing 10Y window (vs. 4th percentile over 3Y); P/B sits at the 3rd percentile over the trailing 10Y window (vs. 4th percentile over 3Y); P/S sits at the 4th percentile over the trailing 10Y window (vs. 4th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 35th percentile within its industry and the 51st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 6.26%, ranking at the 89th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 7.2 points, pointing to a consistent valuation read across both metrics. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. CHARMACY PHAR operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2289 · SEHK: 2289 · 2289
Want the full picture on whether CHARMACY PHAR (2289.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 11.00 | ||||||
| P/B (MRQ) | 0.85 | ||||||
| P/S (TTM) | 0.11 | ||||||
| Dividend Yield | 6.26% | ||||||
| Buyback + Div Yield | 6.26% |